Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

23,113 total articles

FedEx Shares Drop After Strong Quarter but Disappointing 2026 Outlook

FedEx Shares Drop After Strong Quarter but Disappointing 2026 Outlook

FedEx reported fiscal Q4 2026 adjusted EPS of $6.31 on $25 billion in revenue, topping consensus. However, the company issued calendar year 2026 adjusted EPS guidance of $16.90 to $18.10, well below the roughly $19.86 analysts expected, prompting a sharp pre-market decline in its shares as investors digested persistent cost pressures tied to the Fe…

Ambu Shares Drop Sharply After Danske Bank Downgrade

Ambu Shares Drop Sharply After Danske Bank Downgrade

Ambu fell sharply after Danske Bank cut its rating to Sell from Neutral, citing an accelerated rise in competitive pressures within the company’s urology business and broader concerns about near-term growth for the single-use endoscopy specialist. The move follows earlier price-target reductions from UBS and ABG Sundal Collier and pushed the stock …

SK hynix Seeks Nasdaq Listing With Proposed ADS Offering Under 'SKHY'

SK hynix Seeks Nasdaq Listing With Proposed ADS Offering Under 'SKHY'

SK hynix Inc. has submitted a prospectus to list American Depositary Shares (ADSs) on the Nasdaq Global Select Market under the ticker SKHY. Each ADS will represent a fraction of a single common share, with the underlying common shares carrying a par value of ₩5,000. The number of ADSs to be offered and the IPO price have not been decided and will …

Hensoldt Shares Slide as Sector Sell-Off and Technical Weakness Add Pressure

Hensoldt Shares Slide as Sector Sell-Off and Technical Weakness Add Pressure

Hensoldt AG shares fell 4.8% to €67.86, pushing the stock closer to its 52-week low of €64.80 after a sector-wide decline triggered by a Rheinmetall sell-off. Technical indicators have been deteriorating for weeks, management bought shares in late June but the purchase did not halt the decline, and Germany's weakening private sector and losses acro…

Trainline Shares Drop After New CEO Named Amid Market Fragility

Trainline Shares Drop After New CEO Named Amid Market Fragility

Trainline PLC shares fell about 3.8% to trade near 205p after the company disclosed that Ian Brown, formerly of Flutter UK, will take over as chief executive. The leadership change, revealed in an early morning regulatory filing, arrives as the company contends with a difficult regulatory environment and a wider market downturn that has left UK equ…

Kepler Cheuvreux Downgrades Telecom Italia After Strong Rally Reaches Target

Kepler Cheuvreux Downgrades Telecom Italia After Strong Rally Reaches Target

Kepler Cheuvreux lowered its recommendation on Telecom Italia Group from "buy" to "hold," saying the stock's roughly 220% rise in the past 18 months has effectively closed its valuation gap with peers and brought the share price to the brokerage's unchanged €8 target. While several upside scenarios remain possible, the broker judged them unlikely a…

Wendy’s Shares Jump After New CFO and Strategy Chief Named

Wendy’s Shares Jump After New CFO and Strategy Chief Named

Wendy’s stock climbed sharply in pre-market trading after the company named Steve Cirulis as its new Chief Financial Officer and Chief Strategy Officer, effective June 23, 2026. The move, seen as a vote of confidence because of Cirulis’s prior working relationship with CEO Bob Wright, arrived as Wendy’s contends with soft U.S. same-restaurant sales…

Argenx Shares Slide After Vyvgart Myositis Trial Strategy Shift

Argenx Shares Slide After Vyvgart Myositis Trial Strategy Shift

Argenx shares fell 5.7% in Brussels trading after the company updated its late-stage trial plan for Vyvgart in myositis. Management said it will stop pursuing one myositis subtype in the program and will analyze the two remaining subgroups independently, citing less robust evidence of efficacy in one subgroup. J.P. Morgan noted concerns over the DM…